Clinical Trials Arena on MSN5 天
Ractigen’s RAG-01 shows potential in treating non-muscle invasive bladder cancer
The company’s Phase I trial found that patients remained disease free after three months utilising the lowest doses of RAG-01 ...
'Hard to spot' cancer that can go undetected for months or even years
Papillary thyroid cancer is the most common type of thyroid cancer and usually grows slowly. It can remain undetected for a ...
Medscape3 年
Treatment of High-Risk Non-Muscle-Invasive Bladder Cancer
This high-risk group includes patients with high-grade papillary stage Ta or T1 tumors and any patient with carcinoma in situ (CIS), and makes up 15–44% of patients with non-muscle-invasive ...
pharmaphorum4 天
FDA approves Adstiladrin as first gene therapy for NMIBC
for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary ...